| Literature DB >> 33296051 |
Raghavendra Rao K1, Sreenivas Reddy2, Jeet Ram Kashyap1, Vadivelu Ramalingam1, Debabrata Dash1, Vikas Kadiyala1, Suraj Kumar1, Hithesh Reddy1, Jaspreet Kaur1, Ashok Kumar3, Naindeep Kaur1, Anish Gupta1.
Abstract
BACKGROUND: Not every patient achieves normal coronary flow following fibrinolysis in STEMI (ST-segment elevation myocardial infarction). The culprit lesion plaque characteristics play a prominent role in the coronary flow before and during percutaneous coronary intervention. The main purpose was to determine the culprit lesion plaque features by virtual histology-intravascular ultrasound (VH-IVUS) in patients with STEMI following fibrinolysis in relation to baseline coronary angiogram TIMI (thrombolysis in myocardial infarction) flow. Pre-intervention IVUS was undertaken in 61 patients with STEMI after successful fibrinolysis. After the coronary angiogram, they were separated into the TIMI1-2 flow group (n = 31) and TIMI 3 flow group (n = 30). Culprit lesion plaque composition was evaluated by VH-IVUS.Entities:
Keywords: Fibrinolysis; Intravascular ultrasound; Necrotic core; ST-segment elevation myocardial infarction; TIMI flow; Virtual histology-intravascular ultrasound
Year: 2020 PMID: 33296051 PMCID: PMC7726087 DOI: 10.1186/s43044-020-00121-w
Source DB: PubMed Journal: Egypt Heart J ISSN: 1110-2608
Baseline characteristics of the patients (n = 61)
| Variables | TIMI flow 3 ( | TIMI flow 1–2 ( | |
|---|---|---|---|
| Age (years) | 54.63 ± 8.98 | 57.10 ± 14.13 | 0.419 |
| Male, | 26 (86.7%) | 26 (83.9%) | 1.000 |
| Hypertension, | 5 (16.7%) | 11 (35.5%) | 0.095 |
| Diabetes mellitus, | 6 (20%) | 7 (22.6%) | 0.806 |
| Smoking, | 17 (56.7%) | 12 (38.7%) | 0.160 |
| Family history of CAD, | 3 (10%) | 3 (9.7%) | 1.000 |
| BMI (kg/m2) | 25.4 ± 4.17 | 25.10 ± 3.04 | 0.753 |
| BSA (m2) | 1.74 ± 0.13 | 1.74 ± 0.12 | 0.891 |
| Symptom to thrombolysis time (hours) | 4.77 ± 1.60 | 4.67 ± 1.47 | 0.809 |
| Thrombolysis to PCI time (hours) | 16.03 ± 1.37 | 15.71 ± 1.40 | 0.377 |
| Hemoglobin (g/dL) | 13.19 ± 1.85 | 13.31 ± 2.06 | 0.822 |
| Creatinine (mg/dL) | 1.1 ± 0.17 | 1.07 ± 0.18 | 0.485 |
| Total cholesterol (mg/dL) | 152.1 ± 52.85 | 139 ± 30.16 | 0.262 |
| Triglycerides (mg/dL) | 134.1 ± 47.18 | 119.2 ± 40.82 | 0.208 |
| LDL-cholesterol (mg/dL) | 100.8 ± 54.47 | 86.6 ± 33.42 | 0.247 |
| HDL-cholesterol (mg/dL) | 38.18 ± 9.05 | 38.84 ± 11.74 | 0.814 |
| CK-MB (IU/l) | 40 (36.25–53) | 37 (31 − 97.75) | 0.852 |
| Ejection fraction, (%) | 43.40 ± 4.28 | 40.25 ± 6.34 | 0.027 |
| Thrombolysis, | 0.656 | ||
| Streptokinase | 24 (80%) | 22 (71%) | |
| Reteplase | 6 (20%) | 8 (25.8%) | |
| Tenecteplase | 0 (0%) | 1 (3.2%) | |
| GP IIb-IIIa inhibitor use, | 11 (36.7%) | 10 (32.3%) | 0.717 |
| Medications at admission (%) | |||
| Antiplatelets (%) | 2 (6.6%) | 3 (9.6%) | 1.000 |
| Statins (%) | 3 (10%) | 4 (12.9%) | 1.000 |
| Beta blockers (%) | 2 (6.6%) | 5 (16.1%) | 0.425 |
| ACE I/ARBs (%) | 4 (13.3%) | 5 (16.1%) | 1.000 |
| OHAs (%) | 3 (10%) | 5 (16.1%) | 0.707 |
| Insulin (%) | 2 (6.6%) | 1 (3.2%) | 0.612 |
Data are presented as mean ± SD, median (interquartile range), or n (%)
CAD coronary artery disease, BMI body mass index, BSA body surface area, PCI percutaneous coronary intervention, LDL low-density lipoprotein, HDL high-density lipoprotein, CK-MB creatine kinase-myocardial band (IU/l), ACE I angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers, OHA oral hypoglycemic agents
Angiographic characteristics and procedure findings (n = 61)
| Variables | TIMI flow 3 ( | TIMI flow 1–2 ( | |
|---|---|---|---|
| Culprit vessel, | < 0.001 | ||
| LAD | 13 (43.3%) | 28 (90.3%) | |
| LCX | 4 (13.3%) | 1 (3.2%) | |
| RCA | 13 (43.3%) | 2 (6.5%) | |
| Diseased vessels, | |||
| SVD | 17 (56.7%) | 21 (67.7%) | 0.372 |
| DVD | 11 (36.7%) | 6 (19.4%) | 0.132 |
| TVD | 2 (6.7%) | 4 (12.9%) | 0.671 |
| ACC/AHA Lesion type, | 0.350 | ||
| Type A | 14 (46.7%) | 13 (41.9%) | |
| Type B1 | 9 (30%) | 10 (32.3%) | |
| Type B2 | 3 (10%) | 7 (22.6%) | |
| Type C | 4 (13.3%) | 1 (3.2%) | |
| Baseline TIMI flow grade, | < 0.001 | ||
| 1 | 0 (0%) | 6 (19.4%) | |
| 2 | 0 (0%) | 25 (80.6%) | |
| 3 | 30 (100%) | 0 (0%) | |
| Collateral flow grade (Rentrop), | 1.000 | ||
| 0 | 30 (100%) | 30 (96.8%) | |
| 1 | 0 (0%) | 0 (0%) | |
| 2 | 0 (0%) | 1 (3.2%) | |
| 3 | 0 (0%) | 0 (0%) | |
| TIMI Thrombus grading, | 0.662 | ||
| 0 | 27 (90%) | 24 (77.4%) | |
| 1 | 2 (6.7%) | 5 (16.1%) | |
| 2 | 0 (0%) | 0 (0%) | |
| 3 | 1 (3.3%) | 1 (3.2%) | |
| 4 | 0 (0%) | 1 (3.2%) | |
| 5 | 0 (0%) | 0 (0%) | |
| CTFC (baseline angiogram) | 34 (28.82–42) | 50.58 (44.7–61.17) | < 0.001 |
| Quantitative coronary angiography data | |||
| Obstruction diameter (mm) | 0.86 (0.73–1.19) | 0.95 (0.73–1.31) | 0.549 |
| Reference diameter (mm) | 2.55 ± 0.38 | 2.56 ± 0.55 | 0.967 |
| Diameter stenosis (%) | 62.20 ± 10.15 | 59.40 ± 15.25 | 0.404 |
| Area stenosis (%) | 85.62 (78.58–91.32) | 86.51 (70.29–91.07) | 0.399 |
Data are presented as mean ± SD, median (interquartile range), or n (%)
LAD left anterior descending coronary artery, LCX left circumflex coronary artery, RCA right coronary artery, SVD single-vessel disease, DVD double vessel disease, TVD triple vessel disease, TIMI thrombolysis in myocardial infarction, CTFC corrected thrombolysis in myocardial infarction frame count, PCI percutaneous coronary intervention
Gray-scale IVUS findings (n = 61)
| Variables | TIMI flow 3 ( | TIMI flow 1–2 ( | |
|---|---|---|---|
| IVUS lesion length (mm) | 28.95 (19.40–39.62) | 25.20 (19.70–31.90) | 0.299 |
| Proximal reference | |||
| Lumen CSA (mm2) | 8.65 (7.68–9.89) | 9.86 (6.86–11.50) | 0.328 |
| EEM CSA (mm2) | 13.21 (12.03–15.76) | 15.65 (11.68–18.31) | 0.124 |
| Plaque burden (%) | 33.28 (27.37–38.11) | 36.11 (28.37–38.74) | 0.585 |
| Distal reference | |||
| Lumen CSA (mm2) | 5.95 ± 1.93 | 5.36 ± 1.65 | 0.212 |
| EEM CSA (mm2) | 9.21 (6.13–11.49) | 8.48 (6.43–11.56) | 0.828 |
| Plaque burden (%) | 31.40 (26.93–37.27) | 36.92 (33–39.91) | 0.027 |
| Average/Mean Lumen CSA (mm2) | 7.32 (6.39–8.80) | 7.30 (5.60–8.59) | 0.725 |
| Average/Mean EEM CSA (mm2) | 10.95 (9.61–13.31) | 12.36 (8.87–14.93) | 0.213 |
| Lesion measurements | |||
| Lesion minimum luminal diameter (mm) | 1.56 (1.5–1.63) | 1.57 (1.51–1.68) | 0.436 |
| Lesion maximum luminal diameter (mm) | 2.0 (1.82–2.22) | 2.06 (1.82–2.25) | 0.670 |
| Lesion Lumen CSA (mm2) | 2.43 (2.15–2.71) | 2.45 (2.11–2.87) | 0.363 |
| Lesion EEM CSA (mm2) | 13.91 ± 2.94 | 15.71 ± 3.73 | 0.041 |
| Lesion (P + M) CSA (mm2) | 11.45 ± 2.85 | 13.13 ± 3.66 | 0.050 |
| Lesion lumen area stenosis (%) | 67.30 (60.39–71.18) | 66.14 (55.12–71.57) | 0.658 |
| Lesion plaque burden (%) | 81.65 (79.98–84.01) | 82.42 (80.68–85.77) | 0.306 |
| Plaque volume (mm3) | 94.3 (72.22–120.22) | 108.3 (94.10–120.20) | 0.194 |
| Remodeling index | 1.21 (1.06–1.42) | 1.22 (1.03–1.50) | 0.946 |
Data are presented as mean ± SD, median (interquartile range), or n (%)
IVUS intravascular ultrasound, EEM CSA external elastic membrane cross-sectional area, P + M plaque plus media
Fig. 1The virtual histology plaque components in TIMI 1–2 and TIMI 3 groups at the minimum lumen area site (MLS). a, b The absolute plaque components and c, d the relative plaque components at the MLS
Fig. 2The virtual histology plaque components in TIMI 1–2 and TIMI 3 groups over the segment. a, b The absolute volumes of the plaque components and c, d the relative plaque components
Fig. 3Absolute necrotic core volume (left panel) and relative necrotic core percentage (right panel) in the culprit plaque, according to the post-fibrinolysis TIMI flow grade
Fig. 4Receiver operating characteristic (ROC) curves of the gray-scale and VH-IVUS parameters for the determinants of TIMI 1–2 flow